文献速递湿疹皮炎与荨麻疹

不同保湿剂类型预防高危新生儿特应性皮炎:随机双盲平行三组II期试验

Prevention of atopic dermatitis in high-risk neonates via different types of moisturizer application: A randomized, blinded, parallel, three-group, phase II trial (PAF study).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-08-03

该单中心、三平行组、评估者盲法、优越性、个体随机对照II期试验纳入60名至少一名父母或兄弟姐妹患AD的新生儿,随机1:1:1至Fam's Baby保湿剂每日两次(A组)、每日一次(B组)或2e每日一次(C组)至32周龄。主要结局为AD发病时间;A、B、C组AD发生率分别为11/20(55%)、5/20(25%)、10/20(50%)。B组较C组倾向维持皮肤完整更久(中位时间未达到 vs 212天,log-rank p=0.064),B组AD风险倾向更低(以C组为对照的HR 0.36,95%CI 0.12-1.06);无严重不良事件。Fam's Baby保湿剂可能比2e更好地预防AD。

要点

  • Fam's Baby每日一次组AD发生率25%(5/20),2e每日一次组为50%(10/20)。
  • B组较C组倾向维持皮肤完整更久(中位时间未达到 vs 212天,p=0.064)。
  • 以C组为对照,B组AD风险倾向更低(HR 0.36,95%CI 0.12-1.06)。

核心结论

  • Fam's Baby保湿剂可能比2e更好地预防AD,需进一步大规模试验确认其预防婴儿AD的效力。

研究设计与样本

  • 单中心、三平行组、评估者盲法、优越性、个体随机对照II期试验,2020年8月25日至2021年9月28日纳入60名至少一名父母或兄弟姐妹患AD的新生儿,1:1:1随机至A组(Fam's Baby每日两次)、B组(Fam's Baby每日一次)或C组(2e每日一次)至32周龄,主要结局为AD发病时间。

主要发现

  • A、B、C组AD发生率分别为11/20(55%)、5/20(25%)、10/20(50%)。
  • Kaplan-Meier法累积发病率显示B组较C组倾向维持皮肤完整更久(中位时间未达到 vs 212天,log-rank p=0.064)。
  • Cox回归以C组为对照,B组AD风险倾向更低(HR 0.36,95%CI 0.12-1.06)。
  • 所有入组婴儿均未发生严重不良事件。

临床怎么用

  • 对于至少一名父母或兄弟姐妹患AD的高危新生儿,Fam's Baby保湿剂每日一次相比2e每日一次可能更好地预防AD。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of moisturizers in preventing infant atopic dermatitis (AD) remains unclear. We previously showed that using 2e moisturizer of commercial moisturizer (Shiseido Japan Co., Ltd.) at least once a day significantly prevented AD in infants as compared with as-needed petroleum jelly. This trial aimed to determine the effectiveness of twice- or once-daily application of Fam's Baby moisturizer (Fam's Inc.) in preventing AD compared with once-daily 2e moisturizer. METHODS: This trial was a single-centre, three-parallel-group, assessor-blinded, superiority, individually randomized, controlled, phase II trial that was conducted from 25 August 2020 to 28 September 2021. We randomly assigned 60 newborns with at least one parent or sibling who has AD to receive Fam's Baby moisturizer twice daily (Group A) or once daily (Group B), or 2e once daily (Group C) in a 1:1:1 ratio until they were 32 weeks old. The primary outcome was the time of AD onset. RESULTS: Atopic dermatitis was observed in 11/20 (55%), 5/20 (25%) and 10/20 (50%), infants in Groups A, B and C, respectively. Cumulative incidence values for AD according to the Kaplan-Meier method showed that infants in Group B tended to maintain an intact skin for a longer period than those in Group C (median time, not reached [NR] vs. 212 days, log-rank test, p = 0.064). Cox regression analysis showed that the risk of AD tended to be lower in Group B (hazard ratio with group C as control, 0.36; 95% confidential intervals: 0.12-1.06). No serious adverse events occurred in any of the enrolled infants. CONCLUSION: Fam's Baby moisturizer may better prevent AD than 2e. Further large-scale trials should be performed to confirm the efficacy of Fam's Baby moisturizer in preventing AD in infants.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Inuzuka Y, Yamamoto-Hanada K, Kobayashi T, et al. Prevention of atopic dermatitis in high-risk neonates via different types of moisturizer application: A randomized, blinded, parallel, three-group, phase II trial (PAF study). J Eur Acad Dermatol Venereol. 2023. PMID: 37478291. doi:10.1111/jdv.19375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。